Cantor Fitzgerald reiterated their buy rating on shares of Agile Therapeutics (NASDAQ:AGRX) in a research report sent to investors on Friday. The brokerage currently has a $5.00 target price on the specialty pharmaceutical company’s stock.
AGRX has been the topic of a number of other research reports. Royal Bank of Canada reissued a buy rating and set a $10.00 price target on shares of Agile Therapeutics in a research note on Wednesday, October 18th. HC Wainwright set a $8.00 price target on Agile Therapeutics and gave the stock a buy rating in a research note on Friday. ValuEngine lowered Agile Therapeutics from a sell rating to a strong sell rating in a research note on Friday, September 1st. Finally, Janney Montgomery Scott lowered Agile Therapeutics from a buy rating to a hold rating in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Agile Therapeutics has an average rating of Buy and a consensus target price of $9.20.
Agile Therapeutics (NASDAQ:AGRX) traded down $2.24 during mid-day trading on Friday, reaching $2.52. The company had a trading volume of 10,344,800 shares, compared to its average volume of 408,775. Agile Therapeutics has a 12-month low of $1.82 and a 12-month high of $6.70. The stock has a market cap of $45.61, a price-to-earnings ratio of -2.74 and a beta of 2.02. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.14.
Institutional investors have recently modified their holdings of the business. Janney Montgomery Scott LLC purchased a new position in shares of Agile Therapeutics in the 2nd quarter worth $122,000. Royal Bank of Canada raised its position in shares of Agile Therapeutics by 608.0% in the 2nd quarter. Royal Bank of Canada now owns 32,497 shares of the specialty pharmaceutical company’s stock worth $122,000 after buying an additional 27,907 shares during the period. OxFORD Asset Management LLP purchased a new position in shares of Agile Therapeutics in the 3rd quarter worth $161,000. Susquehanna International Group LLP purchased a new position in shares of Agile Therapeutics in the 2nd quarter worth $205,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of Agile Therapeutics in the 2nd quarter worth $309,000. 72.92% of the stock is currently owned by institutional investors.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.